Literature DB >> 21587131

Prognostic factors of pathologic stage IB non-small cell lung cancer.

Motoki Yano1, Hidefumi Sasaki, Satoru Moriyama, Osamu Kawano, Yu Hikosaka, Yoshitaka Fujii.   

Abstract

PURPOSE: In pathologic IB (pIB) non-small cell lung cancer, especially in adenocarcinoma, adjuvant chemotherapy with uracil-tegafur is widely recognized as being effective. The aim of this study was to determine the prognostic factors of pIB disease. PATIENTS AND METHODS: Sixty patients who were diagnosed with pIB disease between 2004 and 2007 were retrospectively analyzed.
RESULTS: Of 60 patients, 22 (36.7%) opted for surgery plus adjuvant chemotherapy with uracil-tegafur, whereas 38 (63.3%) opted for surgery only. The oral administration dose of uracil-tegafur was 400 mg/body. Compliance of adjuvant chemotherapy with uracil-tegafur was 65.5% in 12 months, 57.3% in 24 months. Adjuvant chemotherapy was interrupted in 11 patients because of the recurrence of disease in 3 patients and adverse reaction in 8 patients. Anorexia was the most common adverse reaction. The larger tumor diameter (5 cm<) and p2 pleural invasion were the worse prognostic factors in disease free survival in a univariate analysis and a multivariate analysis (hazard ratio = 0.26 and 0.25; p = 0.028 and 0.032, respectively).
CONCLUSION: The prognosis of the patients with pleural invasion and a tumor diameter >5 cm was poor, and these, partly support the forthcoming classification.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21587131     DOI: 10.5761/atcs.cr.09.01481

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  1 in total

1.  Lung cancer staging: a physiological update.

Authors:  Michael Poullis; James McShane; Mathew Shaw; Steven Woolley; Michael Shackcloth; Richard Page; Neeraj Mediratta
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-03-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.